MedTrace Logo

Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures

NCT02957097 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-01-26

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness of pre-operative administration of gabapentin 900 mg in management of acute post-operative pain in patients undergoing oral and maxillofacial surgical procedures.

Conditions

  • Pain, Postoperative
  • Acute Pain
  • Facial Pain

Interventions

DRUG

Gabapentin

Medication used for management of neuropathic pain conditions

DRUG

Placebo

Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2021-06-30
Completion
2021-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02957097 on ClinicalTrials.gov